Summary of Key Information:
Reporting Period (Quarter/Year): Year ended March 31, 2026
Nature of Filing / Announcement: Outcome of Board Meeting
Date of Board Meeting / Approval: Monday, August 31, 2026 (4:00 PM to 6:00 PM)
Audit Opinion: Not Specified
Auditor's Comment: Not Specified
Key Financial Highlights: Not Specified
Standalone Results: Not Specified
Consolidated Results: Not Specified
Segment-wise Performance: Not Specified
Corporate Actions:
- Dividend declarations: Not Specified
- ESOP Scheme 2021: Terminated and closed upon voluntary and irrevocable surrender of stock options by respective option holders
- ESOP Scheme 2026: Approved for grant of up to 150,000 Employee Stock Options to eligible employees of the Company, including holding, subsidiary and associate companies
- Grant period: Over five years from date of approval
- Shareholder approval: Subject to approval at ensuing Annual General Meeting
- Exercise price: Will be decided by Committee linked to market price, may include discount but not below face value of Rs. 10/- per share
- Exercise period: Vested options can be exercised not earlier than 1 year and maximum 3 years as determined by Committee
- Implementation: Direct route through new issue of equity shares (not secondary acquisition)
- Administration: Nomination and Remuneration Committee designated as Compensation Committee
Other Significant Information:
- ESOP extension: Board decided to extend benefits of ESOP Scheme 2026 to eligible employees who had options under ESOP Scheme 2021